Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 245

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study

Open access
Wong, Maylene, Staszewsky, Lidia, Latini, Roberto, Barlera, Simona, Volpi, Alberto, Chiang, Yann-Tong, Benza, Raymond L, Gottlieb, Sidney O, Kleemann, Thomas D, Rosconi, Franco, Vandervoort, Pieter M, Cohn, Jay N·2002·Journal of the American College of Cardiology

Abstract

OBJECTIVES The objective of the study was to evaluate the effect of an angiotensin receptor blocker on left ventricular (LV) structure and function when added to prescribed heart failure therapy. BACKGROUND The clinical benefit derived from heart failure therapy is attributed to the regression of LV remodeling. METHODS At 302 multinational sites, 5,010 patients in New York Heart Association (NYHA) classification II to IV heart failure taking angiotensin-converting enzyme inhibitor (ACEI) and/or beta-blocker (BB) were randomized into valsartan and placebo groups and followed for a mean of 22.4 months. Serial echocardiographic measurements of left ventricular internal diastolic diameter (LVIDd) and ejection fraction (EF) were recorded. Total study reproducibility calculated to 90% power at 5% significance defined detectable differences of 0.09 cm for LVIDd and 0.86% for EF. RESULTS Baseline LVIDd and EF for valsartan and placebo groups were similar: 3.6 +/- 0.5 versus 3.7 +/- 0.5 (cm/m(2)) and 26.6 +/- 7.3 versus 26.9 +/- 7.0 (%). Mean group changes from baseline over time were compared. Significant decrease in LVIDd and increase in EF began by four months, reached plateau by one year, and persisted to two years in valsartan compared with placebo patients, irrespective of age, gender, race, etiology, NYHA classification, and co-treatment therapy. Changes at 18 months were -0.12 +/- 0.4 versus -0.05 +/- 0.4 (cm/m(2)), p < 0.00001 for LVIDd, and +4.5 +/- 8.9 versus +3.2 +/- 8.6 (%), p < 0.00001 for EF. The exception occurred in patients taking both ACEI and BB as co-treatment, in whom the decrease in LVIDd and increase in EF were no different between valsartan and placebo groups. CONCLUSIONS The Val-HeFT echocardiographic substudy of 5,010 patients with moderate heart failure demonstrated that valsartan therapy taken with either ACEI or BB reversed LV remodeling.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0735-1097(02)02063-6

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 245

Metadata

Authors
Wong, M., Staszewsky, L., Latini, R., Barlera, S., Volpi, A., Chiang, Y.-T., Benza, R. L., Gottlieb, S. O., Kleemann, T. D., Rosconi, F., Vandervoort, P. M., & Cohn, J. N.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2002-09
Volume
40
Issue
5
Pages
970-975
ISSN
0735-1097 (ISSN-L)
OpenAlex
W2137403077
Cited by
245
References
4
FWCI
10.38
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. https://app.cochat.ai/papers/10.1016/s0735-1097(02)02063-6
The paper
Wong, M., Staszewsky, L., Latini, R., Barlera, S., Volpi, A., Chiang, Y.-T., Benza, R. L., Gottlieb, S. O., Kleemann, T. D., Rosconi, F., Vandervoort, P. M., & Cohn, J. N. (2002). Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. Journal of the American College of Cardiology. https://doi.org/10.1016/s0735-1097(02)02063-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.